Hans van Houte, Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 5,825 shares at $14.40 ($84K) on 2025-03-03, disclosed to the SEC on 2025-03-03.
Scheduled sale ($84k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.40 | 5,125 | $74K | 87.5% |
| 2 | $15.13 | 700 | $11K | 12.5% |
| Total | $14.49 avg | 5,825 | $84K | 100% |
| Filing → |
| NRIX | SELL | 2026-05-05 | $233K | — | Filing → |
| NRIX | SELL | 2026-04-30 | $40K | — | Filing → |
| NRIX | SELL | 2026-01-30 | $122K | — | Filing → |